Clinical impact of direct oral anticoagulant measuring in a real-life setting.
Only sparse information exists on the use of direct oral anticoagulant (DOAC) testing and the impact on clinical management. Here, we evaluated the clinical impact of DOAC measurements in a real-life clinical setting. Moreover, number of tests performed in relation to number of DOAC-treated patients was evaluated. Clinical data was systematically retrieved from medical records on all patients who had undergone a DOAC testing at Aarhus University Hospital, Denmark from 2014 until March 2018. Data on consumption of DOACs and DOAC tests during 2012-2017 was retrieved from the MEDical STATistics database and from involved laboratories. A total of 241 DOAC measurements were performed in 234 patients from 2014 to 2018 at our institution. In 88% of patients, DOAC testing was performed in an acute clinical situation; most frequently in patients with acute stroke (53%) or bleedings (26%). Clinical management was explicitly affected by the DOAC testing in 77% of patients. Number of DOAC tests performed in relation to number of DOAC-treated patients in Denmark varied between 0.05% and 0.39% from 2012 to 2015. However, the number increased in 2017 to 2.10% for rivaroxaban-treated, 1.43% for apixaban-treated and 0.74% for dabigatran-treated patients. DOAC testing had a significant impact on clinical management in the majority of patients. The study highlights the importance of availability to specific DOAC tests, especially in institutions handling emergent settings.